CMS approved Respicardia's remede system for outpatient transitional pass-through payment.
Here's what you should know:
1. The approval provides increased reimbursement in the outpatient setting. The pass-through program will become effective Jan. 1, 2019.
2. The remede system is an implantable device that stimulates the phrenic nerve to treat apnea.
3. Respicardia CEO and President Peter Sommerness said, "We are very pleased that CMS will extend supplemental reimbursement of the remede system into the outpatient setting. The majority of remede system procedures are performed in the outpatient setting, so we expect that this payment will provide substantial support to implanting centers."